Segall Bryant & Hamill LLC Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Segall Bryant & Hamill LLC reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.2% in the 4th quarter, Holdings Channel reports. The firm owned 43,442 shares of the specialty pharmaceutical company’s stock after selling 1,430 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in ANI Pharmaceuticals were worth $2,401,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after buying an additional 340,854 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after acquiring an additional 299 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in ANI Pharmaceuticals by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock valued at $14,936,000 after acquiring an additional 8,869 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in ANI Pharmaceuticals by 14.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 1,972 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in ANI Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after purchasing an additional 17,314 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Stock Up 1.8 %

Shares of ANIP opened at $68.36 on Friday. The company’s 50-day moving average price is $60.31 and its 200 day moving average price is $58.31. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.05. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.49 billion, a P/E ratio of -124.29 and a beta of 0.63.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $191,776 over the last three months. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.